SEC Company Response from PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981) (CNSY) — Sep 19, 2019
PLUS THERAPEUTICS, INC. (CNSY) (CIK 0001095981)
Date: Sept. 19, 2019 · CIK: 0001095981 · Accession: 0001564590-19-035067
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-229485
Letter
VIA EDGAR Division of Corporation Finance Securities and Exchange Commission Plus Therapeutics, Inc. Registration Statement on Form S-1 Filed February 1, 2019 File No. 333-229485
Dear Mr. Fay:
Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S‑1 referred to above be accelerated so that it will become effective at 12:00 P.M. Eastern Time on September 23, 2019, or as soon as practicable thereafter.
If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter.
Very truly yours,
PLUS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm pstv-corresp.DOCX.htm Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 September 19, 2019 VIA EDGAR Michael Fay Division of Corporation Finance Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Plus Therapeutics, Inc. Registration Statement on Form S-1 Filed February 1, 2019 File No. 333-229485 Dear Mr. Fay: Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of Plus Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S‑1 referred to above be accelerated so that it will become effective at 12:00 P.M. Eastern Time on September 23, 2019, or as soon as practicable thereafter. If you have any questions or require additional information, please contact Cheston J. Larson, Esq. of Latham & Watkins LLP at (858) 523-5435. Thank you for your assistance and cooperation in this matter. Very truly yours, PLUS THERAPEUTICS, INC. By: /s/ Marc H. Hedrick, M.D. Marc H. Hedrick, M.D. President and Chief Executive Officer cc:Cheston J. Larson, Esq., Latham & Watkins LLP Christopher G. Geissinger, Esq., Latham & Watkins LLP